

Enabling and accelerating biologics and vaccines development for startup companies

**Technologies • Resources • Guidance • Financial Support Industry-Leading Single-Source Drug Development Platforms** 

Scan the QR code to learn more:





# **Enable the Molecule** Program

WuXi Biologics' Enable the Molecule Program works with accelerators, seed/venture capital firms, incubators, and innovation programs on a global-scale to provide startups with the necessary tools and resources to expedite biologics and vaccine development.

The exclusive program benefits include financial incentives, technical support, training, resources and access to world-class technology and drug development platforms all designed to launch startups quickly and on the correct path for accelerated drug development.

#### Eligibility

Startups must be an active participant or referred from a Program Partner.



Get started with up to R&D credits to accelerate



Take advantage of technology platforms with up to \$1,000,000 in technology credits.



Utilize drug development support, education, and guidance from WuXi Biologics experts with up to \$10,000 in support credits.



connected funds and partnerships for technology

Enable the Molecule **Program** 

WuXi Biologics

### **R&D Support**

Platform Technology Access

Resources, Education & Guidance

Investment and Technology Validation


#### **Program Partner Benefits:**

- Achieve faster ROI and lower drug development cost
- Connect to WuXi Biologics venture capital partners
- Offer more expertise and drug development resources
- Provide low risk, "turn-key" development solutions for your startups
- · Work with an industry leading, high-quality, and highly-trusted CRDMO

### **Startup Benefits:**

- Reach key drug development milestones faster
- Conduct projects "Right-First-Time" with expert advice and access to highly-experienced teams
- Streamline project activities via single point of contact, project management system
- Achieve significant cost savings from streamlined activities, fewer vendor transactions and single company audit, contract, and quality agreements
- Reduce IP drift from exposure to many vendors and benefit from the sole accountability that comes from working with one CRDMO

### **Enable the Molecule Program - Essential Structure**



# **WuXi Biologics**

WuXi Biologics is a global Contract Research, Development and Manufacturing Organization (CRDMO) with leading open-access biologics technology platforms. With operations in China, the United States, Ireland, Germany, and Singapore, we offer end-to-end solutions that enable our partners to discover, develop, and manufacture biologics from concept to commercialization for the benefit of patients worldwide.

We are unique in offering a true one-stop target to market integrated service that greatly expedites biologics drug development. With comprehensive capabilities and extensive expertise throughout the entire discovery to commercialization continuum, we enable companies across the globe with highly-vetted and efficient technology platforms.



Over 600 global partners including the top 20 pharmaceutical companies



One-stop offering utilizing multiple global R&D laboratories and GMP manufacturing facilities




World leading CRMDO services with over 350+ biologics to IND and over 35 different product license approvals



Over 12,000 highly trained employees with 500+ industry veterans with 10-30 years of experience across all disciplines

We provide single-source platforms for a variety of biotherapeutics and vaccines produced from mammalian cell culture and microbial fermentation systems.




# Integrated Discovery, Preclinical CMC and GMP Manufacturing

WuXi Biologics' multiple, proprietary biologics discovery platforms can be seamlessly integrated into our various CMC development activities. We have a proven track record of expediting the time to global IND filing and our GMP manufacturing and quality system have been approved by 10 different global regulatory agencies.



# The WuXi Biologics Single Source CRDMO Platform (Target to IND)





# **Expediting the Discovery to IND Timeline**


In a multi-vendor drug development model, project hand-offs, time, risk, and costs that over the course of the discovery to GMP manufacturing continuum can add months to even a year of lost time compared to a single-source vendor approach. Let WuXi Biologics experienced team of experts across all facets of biologics development help get you to the clinic faster and more cost-effectively.

### **Integrated Solutions Shorten Development Time**


Compared to a multi-vendor model, the WuXi Biologics single-source CRDMO model provides the following advantages:


- Faster legal review and lower costs due to only one contract, MSA, QA and audit
- No pause in development activities by switching to another vendor
- Parallel development activities possible
- Sole accountability for all project deliverables and results
- More efficient trouble-shooting and access to technical experts across all development activities
- · Less risk of IP drift
- Geographic-centric facilities reduces shipping costs and logistic hurdles
- · Lower & fewer transaction costs

#### **Multi-Vendor Timeline**



## VS. WuXi Biologics Timeline





## **About WuXi Biologics**

WuXi Biologics is a leading contract research, development and manufacturing organization (CRDMO) that provides end-to-end capabilities to healthcare organizations worldwide. With operations in China, the United States, Ireland, Germany, and Singapore, we enable our partners to effectively and efficiently bring biologics and vaccines to patients worldwide through our comprehensive and high-quality drug development model.

The world's leading global single-source platform from concept to commercialization.

 $wuxibiologics.com \mid info@wuxibiologics.com$ 

